Featured Product Guide - Q4 2020 - 99

0.9% Sodium Chloride Injection, USP
in FLEBOFLEX Plastic Container
DESCRIPTION
Sodium Chloride Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment in single
dose containers for intravenous administration. It contains no antimicrobial agents. The pH ranges from 4.5 to 7.0.
Composition, osmolarity, and ionic concentration are shown below:
0.9% Sodium Chloride Injection, USP contains 9 g/L Sodium Chloride, USP (NaCl) with an osmolarity of 308
mOsmol/L (calc). It contains 154 mEq/L sodium and 154 mEq/L chloride.
The FLEBOFLEX plastic container is fabricated from latex-free polyolefins or polypropylene plastic materials. The solution contact materials do not contain PVC, DEHP, or other plasticizers. The amount of water that can permeate from
inside the container into the overwrap is insufficient to affect the solution significantly. The suitability of the container
materials has been established through biological evaluations, which have shown the container passes Class VI U.S.
Pharmacopeia (USP) testing for plastic containers. These tests confirm the biological safety of the container system.
CLINICAL PHARMACOLOGY
Sodium Chloride Injection, USP has value as a source of water and electrolytes. It is capable of inducing diuresis
depending on the clinical condition of the patient.
INDICATIONS AND USAGE
Sodium Chloride Injection, USP is indicated as a source of water and electrolytes.
0.9% Sodium Chloride Injection, USP is also indicated for use as a priming solution in hemodialysis procedures.
CONTRAINDICATIONS
None known.
WARNINGS
Hypersensitivity
Hypersensitivity and infusion reactions, including hypotension, pyrexia, tremor, chills, urticaria, rash, and pruritus have
been reported with 0.9% Sodium Chloride Injection, USP.
Stop the infusion immediately if signs or symptoms of a hypersensitivity reaction develop, such as tachycardia,
chest pain, dyspnea and flushing. Appropriate therapeutic countermeasures must be instituted as clinically indicated.
Electrolyte Imbalances
Fluid Overload
Depending on the volume and rate of infusion, and the patient's underlying clinical condition, the intravenous administration of Sodium Chloride Injection, USP can cause fluid disturbances such as overhydration/hypervolemia and
congested states, including pulmonary congestion and edema.
Avoid 0.9% Sodium Chloride Injection, USP in patients with or at risk for fluid and/or solute overloading. If use cannot
be avoided, monitor fluid balance, electrolyte concentrations, and acid base balance, as needed and especially during
prolonged use.
Hyponatremia
Sodium Chloride Injection, USP may cause hyponatremia. Hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy, and vomiting. Patients with brain edema are at particular
risk of severe, irreversible and life-threatening brain injury.
The risk of hospital-acquired hyponatremia is increased in patients with cardiac or pulmonary failure, and in patients
with non-osmotic vasopressin release (including SIADH) treated with high volume of Sodium Chloride Injection, USP.
The risk for hyponatremia is increased in pediatric patients, elderly patients, postoperative patients, those with psychogenic polydipsia, and in patients treated with medications that increase the risk of hyponatremia (such as diuretics, certain antiepileptic and psychotropic medications). See Drug Interactions.
Patients at increased risk for developing complications of hyponatremia such as hyponatremic encephalopathy, include pediatric patients, women (in particular pre-menopausal women), patients with hypoxemia, and patients with
underlying central nervous system disease. Avoid Sodium Chloride Injection, USP in patients with or at risk for hyponatremia. If use cannot be avoided, monitor serum sodium concentrations.
Rapid correction of hyponatremia is potentially dangerous with risk of serious neurologic complications. Brain adaptations reducing risk of cerebral edema make the brain vulnerable to injury when chronic hyponatremia is too rapidly
corrected, which is known as osmotic demyelination syndrome (ODS). To avoid complications, monitor serum sodium
and chloride concentrations, fluid status, acid-base balance, and signs of neurologic complications.
Hypernatremia
Hypernatremia may occur with Sodium Chloride Injection, USP. Conditions that may increase the risk of hypernatremia, fluid overload and edema (central and peripheral), include patients with: primary hyperaldosteronism; secondary
hyperaldosteronism associated with, for example, hypertension, congestive heart failure, liver disease (including cirrhosis), renal disease (including renal artery stenosis, nephrosclerosis); and pre-eclampsia.
Certain medications such as corticosteroids or corticotropin, may also increase risk of sodium and fluid retention,
see Drug Interactions.
Avoid Sodium Chloride Injection, USP in patients with, or at risk for, hypernatremia. If use cannot be avoided, monitor
serum sodium concentrations.
Rapid correction of hypernatremia is potentially dangerous with risk of serious neurologic complications. Excessively
rapid correction of hypernatremia is also associated with a risk for serious neurologic complications such as osmotic
demyelination syndrome (ODS) with risk of seizures and cerebral edema.
PRECAUTIONS
Patients with Severe Renal Impairment
Administration of Sodium Chloride Injection, USP in patients with or at risk of severe renal impairment, may result in
hypernatremia and/or fluid overload (see WARNINGS). Avoid Sodium Chloride Injection, USP in patients with severe
renal impairment or conditions that may cause sodium and/or potassium retention, fluid overload, or edema. If use
cannot be avoided, monitor patients with severe renal impairment for development of these adverse reactions.
Drug Interactions
Other Products that Affect Fluid and/or Electrolyte Balance
Administration of Sodium Chloride Injection, USP to patients treated concomitantly with drugs associated with sodium and fluid retention may increase the risk of hypernatremia and volume overload. Avoid use of Sodium Chloride
Injection, USP in patients receiving such products, such as corticosteroids or corticotropin. If use cannot be avoided,
monitor serum electrolytes, fluid balance and acid-base balance.
Lithium
Renal sodium and lithium clearance may be increased during administration of 0.9% Sodium Chloride Injection, USP.
Monitor serum lithium concentrations during concomitant use.
Other Drugs that Increase the Risk of Hyponatremia
Administration of Sodium Chloride Injection, USP in patients treated concomitantly with medications associated with
hyponatremia may increase the risk of developing hyponatremia.
Avoid use of Sodium Chloride Injection, USP in patients receiving products, such as diuretics, and certain antiepileptic and psychotropic medications. Drugs that increase the vasopressin effect reduce renal electrolyte free water
excretion and may also increase the risk of hyponatremia following treatment with intravenous fluids. If use cannot be
avoided, monitor serum sodium concentrations.
Pregnancy
There are no adequate and well controlled studies with Sodium Chloride Injection, USP in pregnant women and animal
reproduction studies have not been conducted with this drug. Therefore, it is not known whether Sodium Chloride
Injection, USP can cause fetal harm when administered to a pregnant woman. Sodium Chloride Injection, USP should
be given during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation
It is not known whether this drug is present in human milk. Because many drugs are present in human milk, caution
should be exercised when Sodium Chloride Injection, USP is administered to a nursing woman.
Pediatric Use
The use of Sodium Chloride Injection, USP in pediatric patients is based on clinical practice. (See DOSAGE AND
ADMINISTRATION).
Closely monitor plasma electrolyte concentrations in pediatric patients who may have impaired ability to regulate
fluids and electrolytes. In very low birth weight infants, excessive or rapid administration of Sodium Chloride Injection,
USP may result in increased serum osmolality and risk of intracerebral hemorrhage.

20MS6112

IV Solutions

Children (including neonates and older children) are at increased risk of developing hyponatremia as well as for
developing hyponatremic encephalopathy.
Geriatric Use
Geriatric patients are at increased risk of developing electrolyte imbalances. Sodium Chloride Injection, USP is known
to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with
impaired renal function. Therefore, dose selection for an elderly patient should be cautious, usually starting at the
low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of
concomitant disease or other drug therapy. Consider monitoring renal function in elderly patients.
ADVERSE REACTIONS
Post-Marketing Adverse Reactions
The following adverse reactions have been identified during post approval use of Sodium Chloride Injection, USP. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably
estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been reported in the post-marketing experience during use of 0.9% Sodium
Chloride Injection, USP and include the following:
General disorders and administration site conditions: Infusion site erythema, injection site streaking, burning sensation, and infusion site urticaria.
Hypersensitvity reactions: Hypotension, pyrexia, tremor, chills, urticaria, rash, and pruritus.
Metabolism and nutrition disorders: Hypernatremia, hyponatremia, hyperchloremic metabolic acidosis.
Nervous System Disorders: Hyponatremic encephalopathy.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic
countermeasures and save the remainder of the fluid for examination if deemed necessary.
OVERDOSAGE
Excessive administration of 0.9% Sodium Chloride Injection, USP can cause hypernatremia. Hypernatremia can lead
to CNS manifestations, including seizures, coma, cerebral edema and death.
Excessive administration of Sodium Chloride Injection, USP can cause fluid overload (which can lead to pulmonary
and/or peripheral edema). See WARNINGS and ADVERSE REACTIONS.
When assessing an overdose, any additives in the solution must also be considered. The effects of an overdose may
require immediate medical attention and treatment.
Interventions include discontinuation of Sodium Chloride Injection, USP administration, dose reduction, and other
measures as indicated for the specific clinical constellation (e.g., monitoring of fluid balance, electrolyte concentrations and acid base balance).
DOSAGE AND ADMINISTRATION
Important Administration Instructions
* Sodium Chloride Injection, USP is intended for intravenous administration using sterile equipment.
* Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air
contained in the primary container.
* Set the vent to the closed position on a vented intravenous administration set to prevent air embolism.
* Use a dedicated line without any connections to avoid air embolism.
* Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to
avoid air embolism due to incomplete evacuation of residual air in the container.
* Prior to infusion, visually inspect the solution for particulate matter and discoloration. The solution should be clear and
there should be no precipitates. Do not administer unless solution is clear, and container is undamaged.
Dosing Information
The choice of product, dosage, volume, rate, and duration of administration is dependent upon the age, weight and
clinical condition of the patient and concomitant therapy, and administration should be determined by a physician
experienced in intravenous fluid therapy.
Introduction of Additives
Additives may be incompatible.
Evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with
a pharmacist, if available.
If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique.
Mix thoroughly when additives have been introduced. After addition, if there is a discoloration and/or the appearance
of precipitates, insoluble complexes or crystals, do not use. Do not store solutions containing additives. Discard any
unused portion.
HOW SUPPLIED
The available sizes of 0.9% Sodium Chloride Injection, USP are shown below:
Size (mL)
NDC
50 (115 units in one carton) 76297-001-11
100 (70 units in one carton) 76297-001-21
250 (28 units in one carton) 76297-001-31
500 (20 units in one carton) 76297-001-01
1000 (10 units in one carton) 76297-001-41
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the
product be stored at 20° to 25°C (68° to 77°F); excursions are permitted between 15° to 30°C (59° to 86°F). [see
USP Controlled Room Temperature.] Store unit in moisture barrier overwrap. Brief exposure up to 40°C (104°F) does
not adversely affect the product.
DIRECTIONS FOR USE OF FLEBOFLEX PLASTIC CONTAINER
For Information on Risk of Air Embolism - see DOSAGE AND ADMINISTRATION.
To Open
Peel off the overwrap and remove solution container. Visually inspect the container. If the outlet port protector is
damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of
the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not
affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner
bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired,
follow directions below.
Preparation for Administration
1. Suspend container from eyelet support.
2. Remove plastic protector from outlet port at bottom of container.
3. Attach administration set. Refer to complete directions accompanying set.
To Add Medication
Additives may be incompatible.
To add medication before solution administration
1. Prepare medication site.
2. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
3. Mix solution and medication thoroughly.
To add medication during solution administration
1. Close clamp on the set.
2. Prepare medication site.
3. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
4. Remove container from intravenous pole and/or turn to an upright position.
5. Mix solution and medication thoroughly.
6. Return container to in-use position and continue administration.
Laboratorios Grifols, S.A.
Murcia - SPAIN
Printed in SPAIN
Rev. 08/2019
GRIFOLS and FLEBOFLEX are trademarks of Grifols, S.A.
GRIFOLS
Laboratorios Grifols, S.A. Calle Marte nº4 - Polígono Industrial Los Llanos
30565 Las Torres de Cotillas- Murcia SPAIN

henryschein.com/medical

GL-FBX-2000009

HEADER

99


http://www.henryschein.com/medical

Featured Product Guide - Q4 2020

Table of Contents for the Digital Edition of Featured Product Guide - Q4 2020

Table of Contents
Featured Product Guide - Q4 2020 - Cover1
Featured Product Guide - Q4 2020 - Table of Contents
Featured Product Guide - Q4 2020 - 3
Featured Product Guide - Q4 2020 - 4
Featured Product Guide - Q4 2020 - 5
Featured Product Guide - Q4 2020 - 6
Featured Product Guide - Q4 2020 - 7
Featured Product Guide - Q4 2020 - 8
Featured Product Guide - Q4 2020 - 9
Featured Product Guide - Q4 2020 - 10
Featured Product Guide - Q4 2020 - 11
Featured Product Guide - Q4 2020 - 12
Featured Product Guide - Q4 2020 - 13
Featured Product Guide - Q4 2020 - 14
Featured Product Guide - Q4 2020 - 15
Featured Product Guide - Q4 2020 - 16
Featured Product Guide - Q4 2020 - 17
Featured Product Guide - Q4 2020 - 18
Featured Product Guide - Q4 2020 - 19
Featured Product Guide - Q4 2020 - 20
Featured Product Guide - Q4 2020 - 21
Featured Product Guide - Q4 2020 - 22
Featured Product Guide - Q4 2020 - 23
Featured Product Guide - Q4 2020 - 24
Featured Product Guide - Q4 2020 - 25
Featured Product Guide - Q4 2020 - 26
Featured Product Guide - Q4 2020 - 27
Featured Product Guide - Q4 2020 - 28
Featured Product Guide - Q4 2020 - 29
Featured Product Guide - Q4 2020 - 30
Featured Product Guide - Q4 2020 - 31
Featured Product Guide - Q4 2020 - 32
Featured Product Guide - Q4 2020 - 33
Featured Product Guide - Q4 2020 - 34
Featured Product Guide - Q4 2020 - 35
Featured Product Guide - Q4 2020 - 36
Featured Product Guide - Q4 2020 - 37
Featured Product Guide - Q4 2020 - 38
Featured Product Guide - Q4 2020 - 39
Featured Product Guide - Q4 2020 - 40
Featured Product Guide - Q4 2020 - 41
Featured Product Guide - Q4 2020 - 42
Featured Product Guide - Q4 2020 - 43
Featured Product Guide - Q4 2020 - 44
Featured Product Guide - Q4 2020 - 45
Featured Product Guide - Q4 2020 - 46
Featured Product Guide - Q4 2020 - 47
Featured Product Guide - Q4 2020 - 48
Featured Product Guide - Q4 2020 - 49
Featured Product Guide - Q4 2020 - 50
Featured Product Guide - Q4 2020 - 51
Featured Product Guide - Q4 2020 - 52
Featured Product Guide - Q4 2020 - 53
Featured Product Guide - Q4 2020 - 54
Featured Product Guide - Q4 2020 - 55
Featured Product Guide - Q4 2020 - 56
Featured Product Guide - Q4 2020 - 57
Featured Product Guide - Q4 2020 - 58
Featured Product Guide - Q4 2020 - 59
Featured Product Guide - Q4 2020 - 60
Featured Product Guide - Q4 2020 - 61
Featured Product Guide - Q4 2020 - 62
Featured Product Guide - Q4 2020 - 63
Featured Product Guide - Q4 2020 - 64
Featured Product Guide - Q4 2020 - 65
Featured Product Guide - Q4 2020 - 66
Featured Product Guide - Q4 2020 - 67
Featured Product Guide - Q4 2020 - 68
Featured Product Guide - Q4 2020 - 69
Featured Product Guide - Q4 2020 - 70
Featured Product Guide - Q4 2020 - 71
Featured Product Guide - Q4 2020 - 72
Featured Product Guide - Q4 2020 - 73
Featured Product Guide - Q4 2020 - 74
Featured Product Guide - Q4 2020 - 75
Featured Product Guide - Q4 2020 - 76
Featured Product Guide - Q4 2020 - 77
Featured Product Guide - Q4 2020 - 78
Featured Product Guide - Q4 2020 - 79
Featured Product Guide - Q4 2020 - 80
Featured Product Guide - Q4 2020 - 81
Featured Product Guide - Q4 2020 - 82
Featured Product Guide - Q4 2020 - 83
Featured Product Guide - Q4 2020 - 84
Featured Product Guide - Q4 2020 - 85
Featured Product Guide - Q4 2020 - 86
Featured Product Guide - Q4 2020 - 87
Featured Product Guide - Q4 2020 - 88
Featured Product Guide - Q4 2020 - 89
Featured Product Guide - Q4 2020 - 90
Featured Product Guide - Q4 2020 - 91
Featured Product Guide - Q4 2020 - 92
Featured Product Guide - Q4 2020 - 93
Featured Product Guide - Q4 2020 - 94
Featured Product Guide - Q4 2020 - 95
Featured Product Guide - Q4 2020 - 96
Featured Product Guide - Q4 2020 - 97
Featured Product Guide - Q4 2020 - 98
Featured Product Guide - Q4 2020 - 99
Featured Product Guide - Q4 2020 - 100
Featured Product Guide - Q4 2020 - 101
Featured Product Guide - Q4 2020 - 102
Featured Product Guide - Q4 2020 - 103
Featured Product Guide - Q4 2020 - 104
Featured Product Guide - Q4 2020 - 105
Featured Product Guide - Q4 2020 - 106
Featured Product Guide - Q4 2020 - 107
Featured Product Guide - Q4 2020 - Cover4
https://www.nxtbook.com/nxtbooks/henryschein/practicepinkflyer_slimjim2021
https://www.nxtbook.com/nxtbooks/henryschein/bqjournal_q3_2021
https://www.nxtbook.com/nxtbooks/henryschein/pharmaceutical_guide_2021
https://www.nxtbook.com/nxtbooks/henryschein/wfg_flu_sale_flyer_2021
https://www.nxtbook.com/nxtbooks/henryschein/medical_annual_ref_guide_2021
https://www.nxtbook.com/nxtbooks/henryschein/equipmenttabloid_q2_2021
https://www.nxtbook.com/nxtbooks/henryschein/bqjournal_q2_2021
https://www.nxtbook.com/nxtbooks/henryschein/medical_federal_flyer_2021spring
https://www.nxtbook.com/nxtbooks/henryschein/medsurg_slimjim_q2_2021
https://www.nxtbook.com/nxtbooks/henryschein/ssnfa_catalog_20212022
https://www.nxtbook.com/nxtbooks/henryschein/sherman_flyer_2021
https://www.nxtbook.com/nxtbooks/henryschein/pol_2021
https://www.nxtbook.com/nxtbooks/henryschein/bqjournal_q1_2021
https://www.nxtbook.com/nxtbooks/henryschein/medsurg_slimjim_q12021
https://www.nxtbook.com/nxtbooks/henryschein/wfg_sale_flyer_2021
https://www.nxtbook.com/nxtbooks/henryschein/medsurg_slimjim_q42020
https://www.nxtbook.com/nxtbooks/henryschein/lab_tabloid_fallwinter2020
https://www.nxtbook.com/nxtbooks/henryschein/equipmenttabloid_fallwinter2020
https://www.nxtbook.com/nxtbooks/henryschein/featuredproductguide_q4_20
https://www.nxtbook.com/nxtbooks/henryschein/medical_federal_flyer_2020
https://www.nxtbook.com/nxtbooks/henryschein/pediatricspotlight_2020
https://www.nxtbook.com/nxtbooks/henryschein/pharmaceutical_guide_2020
https://www.nxtbook.com/nxtbooks/henryschein/featuredproductguide_q3_20
https://www.nxtbook.com/nxtbooks/henryschein/radiology_imaging2020
https://www.nxtbook.com/nxtbooks/henryschein/bqjournal_q3_2020
https://www.nxtbook.com/nxtbooks/henryschein/wfg_sale_flyer_2020
https://www.nxtbook.com/nxtbooks/henryschein/asc_spotlight_2020
https://www.nxtbook.com/nxtbooks/henryschein/equipmenttabloid_spring2020
https://www.nxtbook.com/nxtbooks/henryschein/gems_q22020
https://www.nxtbook.com/nxtbooks/henryschein/criteriongloves
https://www.nxtbook.com/nxtbooks/henryschein/incontrolslimjim_q12020
https://www.nxtbook.com/nxtbooks/henryschein/gems_q12020
https://www.nxtbook.com/nxtbooks/henryschein/asc_spotlight_2019q3
https://www.nxtbook.com/nxtbooks/henryschein/featuredproductguide_q1_19
https://www.nxtbook.com/nxtbooks/henryschein/featuredproductguide_q2_19
https://www.nxtbook.com/nxtbooks/henryschein/generalmedflyer_q3_2019
https://www.nxtbook.com/nxtbooks/henryschein/generalmedflyer_q4_2019
https://www.nxtbook.com/nxtbooks/henryschein/springequipmenttabloid_2019
https://www.nxtbook.com/nxtbooks/henryschein/equipmenttabloid_2019
https://www.nxtbook.com/nxtbooks/henryschein/radiology_imaging2019
https://www.nxtbook.com/nxtbooks/henryschein/pharmaceutical_guide_2019
https://www.nxtbook.com/nxtbooks/henryschein/vaccine_guide_2019
https://www.nxtbook.com/nxtbooks/henryschein/mmcap_2019
https://www.nxtbookmedia.com